Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.JCVI issues recommendation on adolescent MenB vaccination in UK
The Department of Health and Social Care (DHSC) will consider the guidance before making any decisions about adjustments to the NHS Meningitis B (MenB) vaccination schedule. This latest
The Department of Health and Social Care (DHSC) will consider the guidance before making any decisions about adjustments to the NHS Meningitis B (MenB) vaccination schedule. This latest
Known as Telix Manufacturing Solutions North Melbourne (TMSNM), the site is described as the country’s first purpose-built facility to combine radiochemistry laboratories, clinical manufacturing, patient dose administration, and
HBM7575/SKB575 is designed to target thymic stromal lymphopoietin (TSLP) as well as an undisclosed antigen. The long-acting antibody uses a dual mechanism of action. It works to block
The decision is based on results from the Phase III MAJESTY study, which indicated that Gazyva/Gazyvaro achieved a higher rate of complete remission at two years compared to
IBI355 is an Fc-silent, third-generation anti-CD40L antibody that is expected to advance to Phase II trials for immunoglobulin G4 (IgG4)-related disease. Spero plans to launch a global Phase
The agreement grants Novartis access to Chai Discovery’s latest AI models, including its Chai-3 model, to support antibody discovery efforts across a range of therapeutic targets. The partnership
SBT-77-7101 is described as an autologous CAR-Treg cell therapy currently in Phase I clinical development to treat patients with poly-refractory rheumatoid arthritis (RA). These patients with RA have
The Ministry of Health of the Republic of Indonesia (BKPM) has issued a fractionation licence to Takeda, allowing the company to collect and process plasma as part of
The new approvals for the anti-programmed death-1 (PD-1) therapies cover both neoadjuvant (pre-surgery) and adjuvant (post-surgery) treatment and apply to patients regardless of their eligibility for cisplatin. These
Under the deal, Teva will hold exclusive rights to commercialise both intravenous and subcutaneous formulations of the biosimilar once it obtains regulatory approval. The arrangement covers markets, including